131 related articles for article (PubMed ID: 20655987)
1. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas.
Mahtouk K; Tjin EP; Spaargaren M; Pals ST
Biochim Biophys Acta; 2010 Dec; 1806(2):208-19. PubMed ID: 20655987
[TBL] [Abstract][Full Text] [Related]
2. Targeting the HGF/Met signalling pathway in cancer.
Cecchi F; Rabe DC; Bottaro DP
Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
[TBL] [Abstract][Full Text] [Related]
3. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.
Derksen PW; de Gorter DJ; Meijer HP; Bende RJ; van Dijk M; Lokhorst HM; Bloem AC; Spaargaren M; Pals ST
Leukemia; 2003 Apr; 17(4):764-74. PubMed ID: 12682635
[TBL] [Abstract][Full Text] [Related]
4. HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice.
Weimar IS; Weijer K; van den Berk PC; Muller EJ; Miranda N; Bakker AQ; Heemskerk MH; Hekman A; de Gast GC; Gerritsen WR
Br J Cancer; 1999 Sep; 81(1):43-53. PubMed ID: 10487611
[TBL] [Abstract][Full Text] [Related]
5. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies.
Børset M; Seidel C; Hjorth-Hansen H; Waage A; Sundan A
Leuk Lymphoma; 1999 Jan; 32(3-4):249-56. PubMed ID: 10037022
[TBL] [Abstract][Full Text] [Related]
6. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
[TBL] [Abstract][Full Text] [Related]
7. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
8. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
Yap TA; Sandhu SK; Alam SM; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
[TBL] [Abstract][Full Text] [Related]
9. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation.
van der Voort R; Taher TE; Derksen PW; Spaargaren M; van der Neut R; Pals ST
Adv Cancer Res; 2000; 79():39-90. PubMed ID: 10818677
[TBL] [Abstract][Full Text] [Related]
10. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
Gambella M; Palumbo A; Rocci A
Expert Rev Mol Diagn; 2015; 15(7):881-93. PubMed ID: 25967746
[TBL] [Abstract][Full Text] [Related]
11. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
12. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.
You WK; McDonald DM
BMB Rep; 2008 Dec; 41(12):833-9. PubMed ID: 19123972
[TBL] [Abstract][Full Text] [Related]
13. Follicular dendritic cells catalyze hepatocyte growth factor (HGF) activation in the germinal center microenvironment by secreting the serine protease HGF activator.
Tjin EP; Bende RJ; Derksen PW; van Huijstee AP; Kataoka H; Spaargaren M; Pals ST
J Immunol; 2005 Sep; 175(5):2807-13. PubMed ID: 16116166
[TBL] [Abstract][Full Text] [Related]
14. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways.
Bowers DC; Fan S; Walter KA; Abounader R; Williams JA; Rosen EM; Laterra J
Cancer Res; 2000 Aug; 60(15):4277-83. PubMed ID: 10945642
[TBL] [Abstract][Full Text] [Related]
15. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.
Hu B; Guo P; Bar-Joseph I; Imanishi Y; Jarzynka MJ; Bogler O; Mikkelsen T; Hirose T; Nishikawa R; Cheng SY
Oncogene; 2007 Aug; 26(38):5577-86. PubMed ID: 17369861
[TBL] [Abstract][Full Text] [Related]
16. The role of hepatocyte growth factor/c-met interactions in the immune system.
Skibinski G
Arch Immunol Ther Exp (Warsz); 2003; 51(5):277-82. PubMed ID: 14626426
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HGF/MET as therapy for malignancy.
Naran S; Zhang X; Hughes SJ
Expert Opin Ther Targets; 2009 May; 13(5):569-81. PubMed ID: 19397476
[TBL] [Abstract][Full Text] [Related]
18. [A simple view on lung cancer biology: the MET pathway].
Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
[TBL] [Abstract][Full Text] [Related]
19. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells.
Bigelow RL; Cardelli JA
Oncogene; 2006 Mar; 25(13):1922-30. PubMed ID: 16449979
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor (HGF) promotes oligodendrocyte progenitor cell proliferation and inhibits its differentiation during postnatal development in the rat.
Ohya W; Funakoshi H; Kurosawa T; Nakamura T
Brain Res; 2007 May; 1147():51-65. PubMed ID: 17382307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
